Secarna Pharmaceuticals, a biopharmaceutical company focusing on the discovery and development of antisense oligonucleotide (ASO) therapies to address challenging targets, has entered into a research agreement with a global pharmaceutical company to support research and discovery in the field of oncology. Under the agreement, the global pharmaceutical partner will leverage ASOs derived from Secarna’s LNAplus platform in support of anti-cancer therapies the partner is developing and commerc...